Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

The purpose of this study was to determine the effect of human atrial natriuretic peptide (hANP) in patients who underwent coronary artery bypass grafting (CABG) on renal function.

Who Took Part

According to the abstract, 504 patients were involved.

PubMed indexes the participants as older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

Various parameters were measured before and after surgery.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Cardiopulmonary Bypass, Coronary Artery Bypass, Creatinine, Glomerular Filtration Rate, Intraoperative Care and Kidney.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 504 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Journal of the American College of Cardiology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.